Canadian Technology Stocks and Startups
Sales of Merus Labs’ (TSX:MSL) Enablex-Emselex product were down quarter over quarter, but the stock is still undervalued, says Byron Capital Healthcare and Biotech analyst Douglas Loe. Yesterday, after market, Merus reported its Q2, 2013 financial results. The company lost $2.29-million on revenue of $5.84-million. Loe notes that sales of urinary continence drug Enablex-Emselex in [...]
Cantor Fitzgerald analyst Tom Liston says the market is overreacting to Catamaran’s (TSX:CCT) Q1 numbers. This morning, the company released its Q1, 2013 results. Catamaran earned $56.78-million on revenue of to $3.2-billion, an 88% bump over the $1.7-billion the company posted in the first quarter of 2012. While the stock was down immediately after the [...]
Byron Capital analyst Douglas Loe says that ramped up marketing expenses aren’t hitting Novadaq’s (TSX:NDQ) bottom line as much as he expected. Yesterday, before market, Novadaq Technologies reported its Q1, fiscal 2013 numbers. The company lost (U.S.) $2.93-million on revenue of $7.3-million, a topline that was up 53%, year-over-year. CEO Dr. Arun Menawat said revenue [...]
Your doctor walks in to the patient room toting an iPad. He chats for a bit, inspects your latest run in with a kitchen knife, and then pulls up your entire medical history with a couple taps on the screen. He does a check for contraindications with your current medications before prescribing you some painkillers [...]
After a brief halt at the request of the company this morning, shares of CardioComm Solutions (TSXV:EKG) are trading again, but with the stock up just a penny on 52,400 shares, investors are yawning at the news that its HeartCheck Pen, a ECG based heart rhythm monitoring solution, will now offer a thirty minute response [...]
This morning, a dissident group of shareholders of Bioniche Life Sciences (TSX:BNC), led by former Biovail CEO Bill Wells, wrote an open letter to Bioniche Chairman James Rae. The letter, authored by Wells and Greg Gubitz, former General Counsel and Senior Vice President of Corporate Development at Biovail, points out that despite a share price [...]
Byron Capital analyst Douglas Loe says the results Novadaq Technologies (TSX:NDQ) today announced from its PILLAR 2 study underscore his positive assessment of the company as an investment. This morning, Novadaq announced that interim results from the 150 patient PILLAR™II, Perfusion Assessment in Laparoscopic Left Anterior Resection, were presented during the 2013 Society of American [...]
Cantor Fitzgerald analyst Tom Liston says QHR Technologies (TSX:QHR) is starting to fire on all cylinders. This morning, QHR reported its Q4 and fiscal 2012 results. The company earned $431,640 on revenue of of $29.5-million, which was a 23.5% increase over fiscal 2011. CEO Al Hildebrandt said the company gained momentum in the latter half [...]
Byron Capital analyst says the price Canadian pharma giant Valeant Pharmaceuticals is paying for its most recent acquisition target bodes well for the smaller Cipher Pharmaceuticals (TSX:DND). Loe says Valeant’s recently upped offer of $24 for California-based specialty skin care products firm Obagi Medical Products values that firm at (U.S.) $384 million. With revenue of [...]
ProMetic Life Sciences (TSX:PLI) reported its fourth quarter and fiscal 2012 results yesterday. The company narrowed its losses to just $400,000 on revenue of $23.3-million, up from 2011 $17.6-million topline. ProMetic lost $3.3-million last year. CEO Pierre Laurin said he believes the year will set up those to come. “Two thousand twelve was a record [...]
